NCT06684431 (CCHF-NP-1) is a Phase 1 clinical trial of N-pVAX1 in Crimean Congo Hemorrhagic Fever, sponsored by Karolinska Institutet.

Who is sponsoring NCT06684431?

NCT06684431 is sponsored by Karolinska Institutet.

What drugs are being tested in NCT06684431?

Interventions in NCT06684431: N-pVAX1.

What condition does NCT06684431 study?

NCT06684431 studies Crimean Congo Hemorrhagic Fever.

Is NCT06684431 still recruiting?

NCT06684431 is currently completed. Last updated 23 March 2026.

Last reviewed 2026-03-23 · How we verify

NCT06684431: CCHF-NP-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever

Completed Phase 1 Last updated 23 March 2026

What this trial tests

Phase 1 trial testing N-pVAX1 in Crimean Congo Hemorrhagic Fever in 15 participants. Completed in 17 March 2026.

Timeline

12 November 2024

Primary endpoint
17 March 2026

17 March 2026

Quick facts

Lead sponsor	Karolinska Institutet
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	15
Start date	12 November 2024
Primary completion	17 March 2026
Estimated completion	17 March 2026
Sites	1 location across Sweden

Drugs / interventions tested

N-pVAX1 — full drug profile →

Conditions studied

Crimean Congo Hemorrhagic Fever — all drugs for Crimean Congo Hemorrhagic Fever →

Sponsor

Karolinska Institutet

Who can join

Adults 18 to 60, any sex, with Crimean Congo Hemorrhagic Fever. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This First-in-human dose-escalation vaccine phase I study aims to evaluate safety and reactogenicity of the investigational vaccine N-pVAX1, against Crimean Congo Hemorrhagic Fever, delivered by in vivo EP given as three im doses at weeks 0, 4 and 12.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Karolinska Institutet trials

Trials by the same sponsor.

NCT06359262 — Evaluating the Hope@School Prevention Program · NA · not yet recruiting
NCT07289490 — Bilateral vs Unilateral Inguinal Hernia Repairs With an Asymptomatic Inguinal Hernia in Bilateral Hernias · NA · not yet recruiting
NCT06894264 — Emotion Processing and Regulation in People With Intellectual Disability · NA · not yet recruiting
NCT07494266 — Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited · NA · not yet recruiting
NCT07442032 — Cardiovascular Phenotypes in Sepsis · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06684431 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karolinska Institutet
Last refreshed: 23 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06684431.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing